ERBB2 and cancer: Jain and co-workers recently reported that NRG1β expression in the brain microenvironment was associated with resistance to PI3K inhibitors in L-HER2+ brain metastases, providing further support that metastatic site-specific microenvironments can drive TKI resistance in specific cancer cell types (Kodack et al., 2017).